Belimumab Linked to Lower Relapse Risk in Lupus Serositis
A study has found that belimumab is associated with a lower risk of relapse in patients with systemic lupus erythematosus experiencing serositis. Nearly half of the patients in the study experienced multiple relapses, with no significant difference in response rates between corticosteroid-based and corticosteroid-free therapies. The findings suggest that belimumab may be a viable treatment option for those with relapsing serositis.
- ▪The study included 100 adult patients with systemic lupus erythematosus and documented serositis episodes.
- ▪Conventional immunosuppressants did not reduce the risk of serositis relapse, while belimumab showed a significant reduction in risk.
- ▪Nearly half of the patients experienced multiple serositis relapses during follow-up, with a median time to first relapse of 0.83 years.
Opening excerpt (first ~120 words) tap to expand
TOPLINE:In patients with systemic lupus erythematosus (SLE) with serositis episodes, nearly half experienced relapses, with no difference in the response rate between corticosteroid-based and corticosteroid-free anti-inflammatory therapies. Conventional immunosuppressants were not associated with a reduced risk for serositis relapse, whereas belimumab was associated with a lower risk.METHODOLOGY:Researchers conducted a multicentre, real-world, retrospective observational study to assess the efficacy of anti-inflammatory and immunosuppressive therapies in SLE-related serositis.They included 100 adult patients with SLE (mean age at diagnosis, 32.9 years; 80% women) who had documented pericarditis or pleuritis between January 2000 and October 2025 based on clinical and/or imaging…
Excerpt limited to ~120 words for fair-use compliance. The full article is at Medscape.
Discussion
0 commentsMore from Medscape
